News
Get access to our breaking news, and company information
Press Releases
Reflecting on 2024: A Year of Growth, Innovation, and Partnership at Pillar Biosciences
In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted
Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase
Agreement aims to enhance Pillar’s PiVat® bioinformatics platform with downstream reporting capabilities. NATICK, Mass – January 7, 2025 – Pillar Biosciences, Inc. has entered into
Cancer Centers Look to New NGS-Based ‘Frankenpanel’ to Get Fast Info on Clinically Actionable Genes
Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing
Pillar Biosciences to Present Impactful Research Data at 2024 Association for Molecular Pathology (AMP) Annual Meeting
Natick, MA – November 14, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2024 Association for Molecular Pathology (AMP) Annual Meeting
Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid Tumor IVD Kit
Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory
Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina
Enables content for newly launched Illumina MiSeq™ i100 and expands Illumina oncology panel portfolio to include targeted liquid biopsy panels Natick, MA – October 16, 2024